Recent News

• 02.12.2026 - Soligenix Details Recent Progress and Upcoming Milestones
• 12.18.2025 - Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
• 12.17.2025 - Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
• 11.19.2025 - Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
• 11.07.2025 - Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
• 09.29.2025 - Soligenix Announces Closing of $7.5 Million Public Offering

Recent Filings

• 01.23.2026 - 8-K Current report
• 01.23.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.12.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.18.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 11.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]